SCHEMBL3484832

SCHEMBL3484832

CCOC(=O)C(C)(C)c1ccc2[nH]c(-c3ccc(OC(F)(F)F)cc3)cc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.48
KDM4E B2RXH2 6/20 0.42
GAA P10253 2/20 0.42
KMT2A Q03164 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 3/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
POLB P06746 1/20 0.39
PDE2A O00408 1/20 0.39
MMP2 P08253 2/20 0.38
MMP13 P45452 2/20 0.38
MMP14 P50281 2/20 0.38
KCNH2 Q12809 1/20 0.38
SCN10A Q9Y5Y9 1/20 0.38
TRPV1 Q8NER1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485210 0.89 KCNH2 (0.41) KCNQ2KDM4EGAAKMT2AALDH1A1
SCHEMBL3485512 0.88 KCNQ2 (0.62) KCNQ2KDM4EKMT2AALDH1A1HPGD
SCHEMBL13435458 0.88 KCNQ2 (0.48) KCNQ2KDM4EKMT2APTGDR2ALDH1A1
SCHEMBL3485495 0.87 KCNQ2 (0.47) KCNQ2KDM4EKMT2APTGDR2ALDH1A1
SCHEMBL3485857 0.85 PPARG (0.50) KCNQ2KDM4EGAAKMT2APTGDR2
SCHEMBL3485725 0.84 PTGDR2 (0.43) KCNQ2KDM4EKMT2APTGDR2ALDH1A1
SCHEMBL3485536 0.83 CNR2 (0.38) KCNQ2POLBPDE2AKCNH2SCN10A
SCHEMBL3485770 0.83 KCNQ2 (0.42) KCNQ2KDM4EPTGDR2ALDH1A1HPGD
SCHEMBL3485556 0.82 CNR2 (0.52) KCNQ2KDM4EKMT2AALDH1A1HPGD
SCHEMBL3485839 0.82 CDK5 (0.46) KCNQ2KDM4EPTGDR2MMP2MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
EP-2150112-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS Merck & Co., Inc. (US) 2010-02-10 EP disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, CACNA1S, TRPV2 KCNQ2 103/4885KDM4E 2869/4885GAA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.